Also, clinical studies have shown higher ORR and median PFS for alectinib than crizotinib in previously untreated patients with ALK-positive NSCLC, establishing alectinib as a viable first-line option (59, 65). The gene discussed is ALK; the disease is non-small cell lung carcinoma.